Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H (3378) Ratios
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H Ratios
HK:3378's free cash flow for Q2 2019 was $164.88M. For the 2019 fiscal year, HK:3378's free cash flow was decreased by $-173.31M and operating cash flow was $338.19M. See a summary of the company’s cash flow.
| Ratios | Dec 21 | Dec 20 | Dec 19 | Dec 18 | Dec 17 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Net Current Asset Value | $ -7.84B | $ -4.16B | ― | ― | ― |
| Leverage Ratios | |||||
| Net Debt to EBITDA | 9.64 | 3.62 | ― | ― | ― |
| Profitability Margins | |||||
| Return on Assets (ROA) | 2.91% | 2.57% | ― | ― | ― |
| Return on Equity (ROE) | 13.07% | 10.57% | ― | ― | ― |
| Return on Capital Employed (ROCE) | 8.03% | 5.49% | ― | ― | ― |
| Return on Invested Capital (ROIC) | 4.06% | 2.78% | ― | ― | ― |
| Return on Tangible Assets | 2.91% | 3.08% | ― | ― | ― |
| Earnings Yield | 2.01% | 1.56% | ― | ― | ― |
| Efficiency Ratios | |||||
| Cash Conversion Cycle | 1.24 | -5.20 | ― | ― | ― |
| Days of Sales Outstanding | 0.00 | 0.00 | ― | ― | ― |
| Days of Inventory Outstanding | 28.11 | 33.92 | ― | ― | ― |
| Days of Payables Outstanding | 26.87 | 39.12 | ― | ― | ― |
| Operating Cycle | 28.11 | 33.92 | ― | ― | ― |
| Cash Flow Ratios | |||||
| Free Cash Flow Yield | 5.03% | 2.20% | ― | ― | ― |
| Valuation Ratios | |||||
| Enterprise Value | 47.20B | 46.31B | ― | ― | ― |
| EV to EBITDA | 50.49 | 24.42 | ― | ― | ― |
| EV to Sales | 1.84 | 2.62 | ― | ― | ― |
| EV to Free Cash Flow | 24.56 | 53.31 | ― | ― | ― |
| EV to Operating Cash Flow | 24.56 | 32.57 | ― | ― | ― |
| Tax and Other Ratios | |||||
| Tax Burden | 0.78 | 0.75 | ― | ― | ― |
| Interest Burden | 0.76 | 0.75 | ― | ― | ― |
| Research & Development to Revenue | 0.00 | 0.00 | ― | ― | ― |
| SG&A to Revenue | 0.02 | 0.02 | ― | ― | ― |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | ― | ― | ― |
| Income Quality | 4.64 | 4.99 | ― | ― | ― |
Currency in CNY
